How Does Pemvidutide Work? Mechanism of Action, Per the Research
Pemvidutide is an investigational medicine studied in clinical trials as a dual agonist at the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. Published pharmacology describes GLP-1 receptor signalling acting on glucose-dependent insulin release, gastric emptying and appetite pathways, while glucagon receptor signalling in the liver is linked to hepatic lipid handling and energy expenditure. Randomised trials in steatotic liver disease measured liver fat, body weight and liver histology endpoints. Questions about use belong with a prescribing clinician.
What pemvidutide is, in regulatory terms
Pemvidutide is an investigational medicine studied in clinical trials, where it has been characterised as a dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor (PMID 39002641). Its status remains investigational, meaning availability is confined to registered clinical studies conducted under regulatory oversight and ethics review. Published development work has concentrated on metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH) and obesity-related metabolism, with a randomised 24-week trial in MASLD reported in 2025 (PMID 41113119) and a multicentre phase 2b trial in MASH, IMPACT, reporting 24-week results (PMID 41237796).
This page summarises how the published literature describes the molecule's receptor targets and downstream physiology. It separates mechanism that is well established at the level of receptor pharmacology from mechanism that is still proposed or inferred from clinical endpoints.
The two receptor targets
Reviews of multifunctional incretin peptides group pemvidutide with a broader class of molecules engineered to engage more than one metabolic hormone receptor from a single peptide backbone (PMID 40081498). Reviews of emerging hormone-based anti-obesity medications place dual GLP-1 and glucagon receptor agonists alongside single-receptor incretin agents and other combination approaches in the development pipeline (PMID 39676791).
GLP-1 receptor signalling
The GLP-1 receptor is a class B G protein-coupled receptor. In the pharmacology described across incretin reviews, agonist binding couples predominantly to Gs proteins, raising intracellular cyclic AMP and activating protein kinase A and related effectors, which in pancreatic beta cells supports glucose-dependent insulin secretion (PMID 40081498). The same receptor class is expressed in the gastrointestinal tract and in hypothalamic and hindbrain regions, which reviews link to slowed gastric emptying and reduced food intake (PMID 40081498). Interest in GLP-1 receptor expression in central reward circuitry is wide enough that a systematic review of registered trials catalogued GLP-1 receptor agonist studies in substance use disorders (PMID 41696398), which illustrates the breadth of receptor distribution rather than any established effect of pemvidutide itself.
Glucagon receptor signalling
The glucagon receptor is also a class B G protein-coupled receptor, expressed most densely in hepatocytes. Reviews of glucagon receptor agonist combinations describe hepatic receptor activation as raising cyclic AMP and driving hepatic lipid oxidation and energy expenditure, with the counter-regulatory potential to raise hepatic glucose output that motivates pairing glucagon activity with a GLP-1 component (PMID 40734920). The same review frames glucagon receptor agonism as a strategy intended to add a liver-directed and energy-expenditure component to incretin-based weight management (PMID 40734920).
Why a dual agonist design
The design logic reported in reviews is complementarity. GLP-1 receptor activity is described as reducing energy intake through appetite and gastric emptying pathways while supporting glucose-dependent insulin release, and glucagon receptor activity is described as acting mainly on the liver and on energy expenditure (PMID 40734920). Reviews of multifunctional incretin peptides note that balancing the relative potency at each receptor is a central engineering question for this class, because the glucose-raising potential of glucagon receptor activation must be offset by the insulinotropic arm (PMID 40081498).
Pemvidutide has been administered on a weekly schedule in its clinical programme, as reflected in the phase 2b MASH trial that compared weekly pemvidutide with placebo over 24 weeks (PMID 41237796). No dosing information appears on this page; questions about administration belong with a prescribing clinician and, for an investigational medicine, with the trial investigators.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeFrom receptor signalling to measured physiology
Mechanism pages are most useful when the chain from receptor to endpoint is explicit. The table below separates what receptor pharmacology establishes from what clinical trials measured and what remains proposed.
| Step | What the literature describes | Evidence level |
|---|---|---|
| GLP-1 receptor binding | Class B GPCR, Gs coupling, cyclic AMP rise, glucose-dependent insulin secretion (PMID 40081498) | Established receptor pharmacology, reviewed |
| Appetite and gastric emptying | Central and gastrointestinal GLP-1 receptor activity linked to reduced intake and slowed emptying (PMID 40081498) | Established for the receptor class, reviewed |
| Glucagon receptor binding | Hepatic cyclic AMP signalling, lipid oxidation, energy expenditure (PMID 40734920) | Established receptor pharmacology, reviewed |
| Liver fat content | A randomised, double-blind, placebo-controlled study reported reductions in liver fat content with pemvidutide compared with placebo in MASLD (PMID 39002641) | Phase 2 clinical endpoint |
| Liver histology | The 24-week phase 2b IMPACT trial evaluated histological endpoints in biopsy-confirmed MASH against placebo (PMID 41237796) | Phase 2b clinical endpoint |
| Body weight | Randomised controlled work over 24 weeks in MASLD reported changes in body weight alongside hepatic endpoints (PMID 41113119) | Phase 2 clinical endpoint |
| Class-level hepatic benefit | A systematic review and meta-analysis pooled dual and triple GLP-1-based polyagonists in MASLD and MASH (PMID 42529769) | Pooled analysis across agents |
Hepatic effects
The liver is where the two arms of the molecule are proposed to converge. A randomised, double-blind, placebo-controlled study of pemvidutide in MASLD reported reductions in liver fat content relative to placebo, a result the authors framed within GLP-1 and glucagon dual receptor pharmacology (PMID 39002641). A separate 24-week randomised controlled trial in MASLD reported on safety and efficacy over the same duration (PMID 41113119). At the histological level, the IMPACT phase 2b trial assessed weekly pemvidutide against placebo in MASH over 24 weeks in a multicentre, randomised, double-blind design (PMID 41237796). Commentary on EASL 2024 research priorities situated MASLD pharmacotherapy, including incretin-based approaches, among the field's leading questions (PMID 40063921).
Body composition and lean mass
Because glucagon receptor agonism is described as adding an energy-expenditure component, body composition has become a discussion point for this class. A 2025 paper on muscle loss in obesity therapy argued that lean mass should be treated as a therapeutic target and examined trial designs and endpoints suitable for regulatory discussion (PMID 41362110). That paper addresses methodology for the field rather than establishing any body composition outcome for a single agent.
Established mechanism versus proposed mechanism
Three distinctions matter when reading mechanism claims about this molecule.
- Established: the identity of the two receptor targets, reported consistently as the GLP-1 receptor and the glucagon receptor (PMID 39002641).
- Established for the receptor class: the Gs and cyclic AMP signalling pathways and the physiological roles of GLP-1 and glucagon receptor activation, as summarised in incretin pharmacology reviews (PMID 40081498).
- Proposed: the precise contribution of each receptor arm to the hepatic and weight endpoints measured in trials, which published randomised studies described as outcomes rather than as mechanistically partitioned effects (PMID 41113119).
Reviews of glucagon receptor agonist combinations have been explicit that the field is still defining how much of the clinical signal comes from reduced energy intake and how much from altered hepatic lipid handling or energy expenditure (PMID 40734920).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appAdverse Events in Pemvidutide Trials: What Studies Report
Safety reporting travels with mechanism, because much of what researchers reported follows from GLP-1 receptor activity in the gut. The randomised, double-blind, placebo-controlled MASLD study reported gastrointestinal adverse events among the most common events observed with pemvidutide (PMID 39002641). The 24-week randomised controlled trial in MASLD reported on safety alongside efficacy across its treatment groups (PMID 41113119), and the phase 2b IMPACT study reported safety data for weekly pemvidutide against placebo over 24 weeks (PMID 41237796). A GRADE-assessed meta-analysis of randomised controlled trials pooled efficacy and safety data for pemvidutide in MASH (PMID 41879841), and a broader systematic review and meta-analysis did the same across dual and triple GLP-1-based polyagonists in MASLD and steatohepatitis (PMID 42529769). Individual tolerability cannot be read from pooled trial data, and any safety question belongs with a licensed physician.
What the mechanism literature does not yet settle
Several questions remain open in the published record. The relative weighting of GLP-1 versus glucagon receptor activity in producing the hepatic changes reported in randomised trials has not been isolated in those trials (PMID 39002641). Durability beyond the 24-week windows reported to date is also undefined by those studies (PMID 41237796). Meta-analytic work in this area has been explicit about the limited number of randomised trials available for pooling (PMID 41879841).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeRelated reading
For a broader overview of the molecule, its trial programme and its development status, see the pemvidutide learn page.
This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or investigational therapy. Pemvidutide is investigational, and participation in research is decided between a person and qualified trial investigators.
References
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study (Journal of Hepatology, 2025)
- Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial (JHEP Reports, 2025)
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study (Lancet, 2025)
- Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials (Naunyn-Schmiedeberg's Archives of Pharmacology, 2026)
- Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis (Cureus, 2026)
- Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities (Peptides, 2025)
- Emerging concepts in obesity management: focus on glucagon receptor agonist combinations (Drugs in Context, 2025)
- Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article (Indian Journal of Endocrinology and Metabolism, 2024)
- Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions (Journal of Cachexia, Sarcopenia and Muscle, 2025)
- Current priorities in research on metabolic-associated fatty liver disease based on the results of EASL 2024 (Polski Merkuriusz Lekarski, 2025)
- Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov (Addictive Behaviors Reports, 2026)
Frequently asked questions
What receptors does pemvidutide act on?▾
Published trial reports describe pemvidutide as a dual agonist at the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor (PMID 39002641). Reviews of multifunctional incretin peptides place it within a class of single peptides engineered to engage more than one metabolic hormone receptor at once (PMID 40081498). Both targets are class B G protein-coupled receptors.
How is the GLP-1 receptor arm described in the literature?▾
Incretin pharmacology reviews describe GLP-1 receptor activation as coupling to Gs proteins and raising cyclic AMP, which supports glucose-dependent insulin secretion in beta cells, while receptor populations in the gut and brain are linked to slowed gastric emptying and reduced food intake (PMID 40081498). Those descriptions apply to the receptor class rather than to any single agent.
What does glucagon receptor agonism contribute?▾
Reviews of glucagon receptor agonist combinations describe hepatic glucagon receptor activation as raising cyclic AMP and increasing hepatic lipid oxidation and energy expenditure, with a counter-regulatory potential to raise glucose output that pairing with a GLP-1 component is intended to offset (PMID 40734920). The precise contribution of each arm to clinical endpoints remains a proposed rather than isolated mechanism.
What did randomised trials measure?▾
A randomised, double-blind, placebo-controlled study reported reductions in liver fat content with pemvidutide compared with placebo in MASLD (PMID 39002641). A separate 24-week randomised controlled trial reported safety and efficacy in MASLD (PMID 41113119), and the phase 2b IMPACT study assessed weekly pemvidutide against placebo in steatohepatitis over 24 weeks (PMID 41237796).
What adverse events have studies reported?▾
The placebo-controlled MASLD study reported gastrointestinal adverse events among the most common events observed (PMID 39002641), and the phase 2b IMPACT trial reported safety data for weekly pemvidutide versus placebo over 24 weeks (PMID 41237796). A GRADE-assessed meta-analysis pooled efficacy and safety across randomised trials (PMID 41879841). Individual tolerability questions belong with a licensed physician.
What is the regulatory status of pemvidutide?▾
Pemvidutide remains an investigational medicine evaluated in clinical trials, with randomised phase 2 and phase 2b results published in steatotic liver disease and steatohepatitis (PMID 41113119, PMID 41237796). Availability is confined to registered studies under regulatory and ethics oversight. Any question about eligibility, access or use is a matter for a prescribing clinician or trial investigator.
Why is body composition discussed with this drug class?▾
Because glucagon receptor agonism is described as adding an energy-expenditure component, body composition has become a field-level question. A 2025 paper argued that muscle loss during obesity therapy should be treated as a therapeutic target and examined trial designs and endpoints suitable for regulatory discussion (PMID 41362110). That work addresses methodology rather than establishing outcomes for a single agent.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.